CO6180426A2 - Compuesto para el tratamiento de la hepatitis b - Google Patents

Compuesto para el tratamiento de la hepatitis b

Info

Publication number
CO6180426A2
CO6180426A2 CO09097263A CO09097263A CO6180426A2 CO 6180426 A2 CO6180426 A2 CO 6180426A2 CO 09097263 A CO09097263 A CO 09097263A CO 09097263 A CO09097263 A CO 09097263A CO 6180426 A2 CO6180426 A2 CO 6180426A2
Authority
CO
Colombia
Prior art keywords
alkyl
hydrogen
cycloalkyl
alkylso2
tetrahydrofuranyl
Prior art date
Application number
CO09097263A
Other languages
English (en)
Inventor
Robert G Gentles
Xiaofan Zheng
Min Ding
Yong Tu
Ying Han
Piyasena Hewawasam
John F Kadow
John A Bender
Kap-Sun Yeung
Katharine Grant-Young
Thomas W Hudyma
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO6180426A2 publication Critical patent/CO6180426A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

1.- Un compuesto de la fórmula Icaracterizado porque:R1 es CO2R5 o CONR6R7; R2 esR3 es hidrógeno, halo, alquilo, alquenilo, hidroxi, benciloxi, o alcoxi; R4 es cicloalquilo; R5 es hidrógeno o alquilo; R6 es hidrógeno, alquilo, alquiloSO2, alqueniloSO2, cicloalquiloSO2, (cicloalquilo) alquiloSO2, haloalquiloSO2, (R9) (R10)NSO2, o (R11)SO2;R7 es hidrógeno o alquilo; R8 es hidrógeno, alquilo, cicloalquilo, (cicloalquilo)alquilo, hidroxialquilo, alcoxialquilo, alquilcarbonilo, cicloalquilcarbonilo, haloalquilcarbonilo, alcoxicarbonilo, alquiloSO2, cicloalquiloSO2, haloalquiloSO2, aminocarbonilo, (alquilamino) carbonilo, (dialquilamino) carbonilo, bencilo, benciloxicarbonilo, o piridinilo; R9 es hidrógeno o alquilo; R10 es hidrógeno o alquilo; R11 es azetidinilo, pirrolidinilo, piperidinilo, N-(R12)piperazinilo, morfolinilo, tiomorfolinilo, homopiperidinilo, homomorfolinilo, tetrahidrofuranilo, tetrahidropiranilo, (tetrahidrofuranil)alquilo, o (tetrahidropiranil) alquilo; y R12 es hidrógeno o alquilo; o una sal farmacéuticamente aceptable del mismo.
CO09097263A 2007-03-14 2009-09-10 Compuesto para el tratamiento de la hepatitis b CO6180426A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89488707P 2007-03-14 2007-03-14
US98947407P 2007-11-21 2007-11-21

Publications (1)

Publication Number Publication Date
CO6180426A2 true CO6180426A2 (es) 2010-07-19

Family

ID=39477552

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09097263A CO6180426A2 (es) 2007-03-14 2009-09-10 Compuesto para el tratamiento de la hepatitis b

Country Status (19)

Country Link
US (1) US7547690B2 (es)
EP (1) EP2118109B1 (es)
JP (1) JP5232178B2 (es)
KR (1) KR20100015304A (es)
CN (1) CN101657455B (es)
AR (1) AR065772A1 (es)
AU (1) AU2008226639B2 (es)
BR (1) BRPI0808763A2 (es)
CA (1) CA2681093A1 (es)
CL (1) CL2008000751A1 (es)
CO (1) CO6180426A2 (es)
EA (1) EA016614B1 (es)
IL (1) IL200905A0 (es)
MX (1) MX2009009473A (es)
NZ (1) NZ579342A (es)
PE (1) PE20090648A1 (es)
TW (1) TW200848058A (es)
WO (1) WO2008112473A1 (es)
ZA (1) ZA200906129B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1688420A4 (en) * 2003-11-19 2008-10-22 Japan Tobacco Inc 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
SI2209789T1 (sl) * 2007-11-20 2012-06-29 Bristol Myers Squibb Co Ciklopropil zliti indolobenzazepin hcv ns5b inhibitorji
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
CN101910177B (zh) 2007-12-24 2013-08-28 泰博特克药品公司 作为丙型肝炎病毒抑制剂的大环吲哚
WO2009120745A1 (en) * 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
EP2280978B1 (en) * 2008-03-27 2013-04-24 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
JP2011515496A (ja) * 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー ジオキソランおよびジオキソラノン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
KR20120120190A (ko) 2009-12-07 2012-11-01 타가셉트 인코포레이티드 신경원성 니코틴 아세틸콜린 수용체 리간드인 ３，６?디아자비시클로［３．１．１］헵탄
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
WO2014011863A1 (en) * 2012-07-12 2014-01-16 Targacept, Inc. Method of treatment with 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane
KR20150038122A (ko) * 2012-07-18 2015-04-08 브리스톨-마이어스 스퀴브 홀딩스 아일랜드 (4bS,5aR)-12-시클로헥실-N-(N,N-디메틸술파모일)-3-메톡시-5a-((1R,5S)-3-메틸-3,8-디아자비시클로[3.2.1]옥탄-8-카르보닐)-4b,5,5a,6-테트라히드로벤조[3,4]시클로프로파[5,6]아제피노[1,2-a]인돌-9-카르복스아미드의 제조를 위한 신규 방법 및 중간체
BR112018068638A2 (pt) 2016-03-15 2019-02-05 Bayer Cropscience Ag sulfonamidas substituídas para controle de pragas animais
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
CN110028510A (zh) * 2019-05-22 2019-07-19 南京合巨药业有限公司 一种3-甲基-3,6-二氮杂-双环[3,1,1]庚烷二盐酸盐的制备方法
WO2021089673A1 (de) 2019-11-07 2021-05-14 Bayer Aktiengesellschaft Substituierte sulfonylamide zur bekämpfung tierischer schädlinge

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE428714T1 (de) 2004-02-24 2009-05-15 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
EP1807397A2 (en) 2004-10-26 2007-07-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456167B2 (en) 2006-05-25 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

Also Published As

Publication number Publication date
EA016614B1 (ru) 2012-06-29
ZA200906129B (en) 2010-11-24
KR20100015304A (ko) 2010-02-12
BRPI0808763A2 (pt) 2014-09-16
CL2008000751A1 (es) 2008-07-25
AU2008226639B2 (en) 2012-07-19
PE20090648A1 (es) 2009-05-29
US20080227769A1 (en) 2008-09-18
WO2008112473A1 (en) 2008-09-18
JP2010521476A (ja) 2010-06-24
MX2009009473A (es) 2009-09-15
AR065772A1 (es) 2009-07-01
TW200848058A (en) 2008-12-16
CN101657455B (zh) 2013-02-06
EP2118109A1 (en) 2009-11-18
AU2008226639A1 (en) 2008-09-18
EP2118109B1 (en) 2014-11-26
EA200901241A1 (ru) 2010-02-26
CA2681093A1 (en) 2008-09-18
JP5232178B2 (ja) 2013-07-10
CN101657455A (zh) 2010-02-24
US7547690B2 (en) 2009-06-16
IL200905A0 (en) 2010-05-17
NZ579342A (en) 2011-07-29

Similar Documents

Publication Publication Date Title
CO6180426A2 (es) Compuesto para el tratamiento de la hepatitis b
AR061008A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo
GEP20125456B (en) Azetidines as mek inhibitors for the treatment of proliferative diseases
IN2012DN00999A (es)
AR061053A1 (es) Inhibidores ns5b del virus de hepatitis c de indolobenzazepina fusionados a ciclopropilo
AR057810A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica
GEP20084421B (en) Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
AR067528A1 (es) Eteres heterociclicos sustituidos y su uso en trastornos del snc
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
MY144622A (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
RS20090249A (en) Spiroketone acetyl-coa carboxylase inhibotors
TW200738242A (en) Dihydropteridinones in the treatment of respiratory diseases
TW200718689A (en) 2-Amino-quinazolin-5-ones
IL177962A0 (en) Compounds and methods for treating dyslipidemia
JP2010521483A5 (es)
AR055165A1 (es) Inhibidores ns5b de vhc de indolobenzacepina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la hepatitis c.
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
AR035991A1 (es) Derivados de benzimidazoles e imidazopiridinas, un procedimiento para su preparacion, composiciones farmaceuticas, un procedimiento para su preparacion, y un medicamento utiles como inhibidores de la replicacion del virus sincitial respiratorio
MX2012007420A (es) Analogos para el tratamiento o prevencion de infecciones de flavivirus.
GB0413087D0 (en) Therapeutic compounds
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
MX2007004183A (es) Derivados de benzoimidazol utiles como agentes antiproliferacion.
CO6251359A2 (es) Compuestos de indolobenzazepina sustituida por heteroarilo
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof

Legal Events

Date Code Title Description
FG Application granted